Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 3, 2009, Pages 317-334

  Cook, Stéphane ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

coronary artery bypass grafting (CABG); coronary artery disease; diabetes mellitus; percutaneous coronary intervention (PCI)

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; BARE METAL STENT; CARDIOGENIC SHOCK; CLINICAL DECISION MAKING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DIABETES MELLITUS; DRUG ELUTING STENT; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; REVIEW; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; SYMPTOM; UNSTABLE ANGINA PECTORIS;

ALGORITHMS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, CARDIOGENIC; STENTS; VASCULAR SURGICAL PROCEDURES;

EID: 66549097687     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.12.002     Document Type: Review

References (69)

1. Seidell J.C. Obesity, insulin resistance and diabetes - a worldwide epidemic. The British Journal of Nutrition 2000 (2000) S5-S8
2. Kopelman P.G., and Hitman G.A. Diabetes. Exploding type II. Lancet 352 Suppl. 4 (1998) SIV5
3. Cook S., and Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundamental & Clinical Pharmacology 16 (2002) 441-453
4. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine 14 Suppl. 5 (1997) S1-85
5. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The American Journal of Cardiology 93 (2004) 136-141
6. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
7. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. The Journal of the American Medical Association 289 (2003) 76-79
8. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the 'Yin-Yang' effect-a Chinese concept for a worldwide pandemic. Swiss Medical Weekly 136 (2006) 103-113
9. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine 339 (1998) 229-234
10. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321 (2000) 405-412
11. Group D.S., and on behalf of the European Diabetes Epidemiology G. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine 161 (2001) 397-405
12. Stein B., Weintraub W.S., Gebhart S.S.P., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91 (1995) 979-989
13. Kip K.E., Faxon D.P., Detre K.M., et al. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94 (1996) 1818-1825
14. Wenaweser P., Daemen J., Zwahlen M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. Journal of the American College of Cardiology 52 (2008) 1134-1140
15. Stettler C., Allemann S., Wandel S., et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. British Medical Journal 337 (2008) a1331
16. Cook S., Meier B., and Windecker S. Sirolimus-eluting versus paclitaxel-eluting stents: are there differences in reality?. The Internet Journal of Cardiology (2007) 19-25 Spring
17. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
18. Baumgart D., Klauss V., Baer F., et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Journal of the American College of Cardiology 50 (2007) 1627-1634
19. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. The New England Journal of Medicine 357 (2007) 1393-1402
20. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. The New England Journal of Medicine 356 (2007) 989-997
21. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. The New England Journal of Medicine 356 (2007) 1030-1039
22. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
23. Carson J.L., Scholz P.M., Chen A.Y., et al. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. Journal of the American College of Cardiology 40 (2002) 418-423
24. Mohammadi S., Dagenais F., Mathieu P., et al. Long-term impact of diabetes and its comorbidities in patients undergoing isolated primary coronary artery bypass graft surgery. Circulation 116 (2007) I-220-I-225
25. Leavitt B.J., Sheppard L., Maloney C., et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 110 (2004) II-41-II-44
26. Tatoulis J., Buxton B.F., and Fuller J.A. Patencies of 2,127 arterial to coronary conduits over 15 years. The Annals of Thoracic Surgery 77 (2004) 93-101
27. Stevens L.M., Carrier M., Perrault L.P., et al. Influence of diabetes and bilateral internal thoracic artery grafts on long-term outcome for multivessel coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery 27 (2005) 281-288
28. de Jaegere P.P.T., and Suyker W.J.L. Off-pump coronary artery bypass surgery. Heart 88 (2002) 313-318
29. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularization. The Journal of the American Medical Association 293 (2005) 1501-1508
30. Bravata D.M., Gienger A.L., McDonald K.M., et al. Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Annals of Internal Medicine 147 (2007) 703-716
31. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The New England Journal of Medicine 335 (1996) 217-225
32. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96 (1997) 1761-1769
33. Feit F., Brooks M.M., Sopko G., et al. Long-term clinical outcome in the bypass angioplasty revascularization investigation registry: comparison with the randomized trial. Circulation 101 (2000) 2795-2802
34. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. The final 10-year follow-up results from the BARI randomized trial. Journal of the American College of Cardiology 49 (2007) 1600-1606
35. Henderson R.A., Pocock S.J., Sharp S.J., et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised intervention treatment of angina. [see comments]. Lancet 352 (1998) 1419-1425
36. King S.B., Lembo N.J., Weintraub W.S., et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. The New England Journal of Medicine 331 (1994) 1044-1050
37. CABRI Trial Participants. First-year results of CABRI (coronary angioplasty versus bypass revascularisation investigation). Lancet 346 (1995) 1179-1184
38. Sedlis S.P., Morrison D.A., Lorin J.D., et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. Journal of the American College of Cardiology 40 (2002) 1555-1566
39. Serruys P.W., Ong A.T.L., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. Journal of the American College of Cardiology 46 (2005) 575-581
40. Booth J., Clayton T., Pepper J., et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). Circulation 118 (2008) 381-388
41. Rodriguez A.E., Baldi J., Pereira C.F., et al. Five-year follow-up of the argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). Journal of the American College of Cardiology 46 (2005) 582-588
42. Hueb W., Lopes N.H., Gersh B.J., et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115 (2007) 1082-1089
43. Mercado N., Wijns W., Serruys P.W., et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. The Journal of Thoracic and Cardiovascular Surgery 130 (2005) 512-519
44. Serruys, P., What have we learned from ARTS I and ARTS II? AHA, special session, November 4th. 2007, AHA/ESC joint session: multivessel coronary artery disease - stents vs CABG:room W415a.
45. Serruys P.W., Colombo A., Morice M.C., et al. Arterial revascularisation therapies study part II - sirolimus-eluting stents for the treatment of patients with multivessel de novocoronary artery lesions. EuroIntervention 1 (2005) 147-156
46. Rodriguez A.E., Maree A.O., Mieres J., et al. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. European Heart Journal 28 (2007) 2118-2125
47. Yang J.H., Gwon H.-C., Cho S.J., et al. Comparison of coronary artery bypass grafting with drug-eluting stent implantation for the treatment of multivessel coronary artery disease. The Annals of Thoracic Surgery 85 (2008) 65-70
48. Javaid A., Steinberg D.H., Buch A.N., et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 116 (2007) I-200-I-206
49. Yang Z.K., Shen W.F., Zhang R.Y., et al. Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. Journal of Interventional Cardiology 20 (2007) 10-16
50. Briguori C., Condorelli G., Airoldi F., et al. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. The American Journal of Cardiology 99 (2007) 779-784
51. Lee M.S., Jamal F., Kedia G., et al. Comparison of bypass surgery with drug[hyphen (true graphic)]eluting stents for diabetic patients with multivessel disease. International Journal of Cardiology 123 (2007) 34-42
52. Hannan E.L., Wu C., Walford G., et al. Drug-eluting stents versus coronary-artery bypass grafting in multivessel coronary disease. The New England Journal of Medicine 358 (2008) 331-341
53. Hannan E.L., Racz M.J., Walford G., et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. The New England Journal of Medicine 352 (2005) 2174-2183
54. Kapur A. Coronary artery revascularisation in diabetes. The CARDia trial. European Heart Journal (2008) Hotlines II. Session 1694-1695: ESC, September 1
55. Serruys, P.W.; Mohr, F.W.; investigators obotS., The Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery: the SYNTAX study. New Engl J Med 359: in press.
56. Harjai K.J., Stone G.W., Boura J., et al. Comparison of outcomes of diabetic and nondiabetic patients undergoing primary angioplasty for acute myocardial infarction. The American Journal of Cardiology 91 (2003) 1041-1045
57. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomisned trials. Lancet 361 (2003) 13-20
58. Grines C., Patel A., Zijlstra F., et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. American Heart Journal 145 (2003) 47-57
59. Timmer J.R., Ottervanger J.P., Thomas K., et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. European Heart Journal 25 (2004) 926-931
60. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine 344 (2001) 1895-1903
61. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. European Heart Journal 28 (2007) 443-449
62. Stuckey T.D., Stone G.W., Cox D.A., et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal of Cardiology 95 (2005) 1-7
63. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. [see comments]. The New England Journal of Medicine 341 (1999) 625-634
64. White H.D., Assmann S.F., Sanborn T.A., et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) trial. Circulation 112 (2005) 1992-2001
65. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 102 (2000) 1014-1019
66. Roffi M., Chew D.P., Mukherjee D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104 (2001) 2767-2771
67. Wallentin L., Lagerqvist B., Husted S., et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II investigators. Fast revascularisation during instability in coronary artery disease. Lancet 356 (2000) 9-16
68. Norhammar A., Malmberg K., Diderholm E., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. Journal of the American College of Cardiology 43 (2004) 585-591
69. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIB/IIIA inhibitor tirofiban. The New England Journal of Medicine 344 (2001) 1879-1887